Evidence map›Paper›PMID 24922186›Full record

ArticleAmerican journal of respiratory cell and molecular biology2015

Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice.

Jun Yang, Jennifer Bratt, Lisa Franzi, Jun-Yan Liu, Guodong Zhang, Amir A Zeki, Christoph F A Vogel, Keisha Williams, Hua Dong, Yanping Lin and 3 more

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Epistatic contributions to human traits via transcription factor mechanisms.medRxiv : the preprint server for health sciences · 2025
    Article
  3. Article
  4. Inhibitory Activity of Glycosides fromJournal of microbiology and biotechnology · 2024
    Article
  5. Article
  6. Article
  7. Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
  9. Inhibitory Activity of NaturalPlants (Basel, Switzerland) · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Jun Yang1 Department of Entomology and Nematology and Comprehensive Cancer Center.
Jennifer Bratt
Lisa Franzi
Jun-Yan Liu
Guodong Zhang
Amir A Zeki
Christoph F A Vogel
Keisha Williams
Hua Dong
Yanping Lin
Sung Hee Hwang
Nicholas J Kenyon
Bruce D Hammock
Sylvester Comprehensive Cancer Center · USSleepMed · USUniversity of California, Davis · US

Funding

Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1987 to 2021
$50.1M
UC Davis Clinical and Translational Science CenterUL1TR000002 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2012 to 2015
$12.2M
TRAINING IN COMPARATIVE LUNG BIOLOGY AND MEDICINET32HL007013 · NHLBI · UNIVERSITY OF CALIFORNIA DAVIS · PI Elena Goncharova, Nicholas J. KENYON · 1985 to 2026
$10.1M
West Coast Central Comprehensive Metabolomics Resource Core (WC3MRC)U24DK097154 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FIEHN, OLIVER · 2012 to 2017
$9.9M
HYDROLYTIC ENZYMES IN THE METABOLISM OF TOXINSR01ES002710 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1985 to 2018
$4.0M
UC Davis Clinical and Translational Science CenterKL2TR000134 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2012 to 2015
$3.1M
L-arginine as a therapy in severe asthmaR01HL105573 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J. · 2012 to 2016
$1.9M
The Modulation of Eotaxin Expression by Statins: Implications for Asthma TherapyK08HL114882 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ZEKI, AMIR A. · 2014 to 2016
$435k
NCATS NIH HHS KL2 TR000134NCATS NIH HHS TR000134NCATS NIH HHS UL1 TR000002NCATS NIH HHS UL1TR000002NHLBI NIH HHS K08 HL114882NHLBI NIH HHS R01 HL105573NHLBI NIH HHS T32 HL007013NHLBI NIH HHS T32HL007013NIDDK NIH HHS U24 DK097154NIEHS NIH HHS P42 ES004699NIEHS NIH HHS R01 ES002710
6 · The paper itself

Abstract

Control of airway inflammation is critical in asthma treatment. Soluble epoxide hydrolase (sEH) has recently been demonstrated as a novel therapeutic target for treating inflammation, including lung inflammation. We hypothesized that pharmacological inhibition of sEH can modulate the inflammatory response in a murine ovalbumin (OVA) model of asthma. BALB/c mice were sensitized and exposed to OVA over 6 weeks. A sEH inhibitor (sEHI) was administered for 2 weeks. Respiratory system compliance, resistance, and forced exhaled nitric oxide were measured. Lung lavage cell counts were performed, and selected cytokines and chemokines in the lung lavage fluid were measured. A LC/MS/MS method was used to measure 87 regulatory lipids mediators in plasma, lung tissue homogenates, and lung lavage fluid. The pharmacological inhibition of sEH increased concentrations of the antiinflammatory epoxy eicosatrienoic acids and simultaneously decreased the concentrations of the proinflammatory dihydroxyeicosatrienoic acids and dihydroxyoctadecenoic acids. All monitored inflammatory markers, including FeNO levels, and total cell and eosinophil numbers in the lung lavage of OVA-exposed mice were reduced by sEHI. The type 2 T helper cell (Th2) cytokines (IL-4, IL-5) and chemokines (Eotaxin and RANTES) were dramatically reduced after sEHI administration. Resistance and dynamic lung compliance were also improved by sEHI. We demonstrated that sEHI administration attenuates allergic airway inflammation and airway responsiveness in a murine model. sEHI may have potential as a novel therapeutic strategy for allergic asthma.

Indexed as

AnimalsAsthmaCytokinesDisease Models, AnimalEicosanoic AcidsEnzyme InhibitorsEpoxide HydrolasesInflammationInflammation MediatorsMaleMiceTh2 CellsVascular ResistanceCytokinesEicosanoic AcidsEnzyme InhibitorsEphx2 protein, mouseEpoxide HydrolasesInflammation Mediatorsasthmainflammationlipid mediatorssoluble epoxide hydrolasetype 2 T helper cell cytokines

Identifiers

PMID24922186
PMCPMC4370250
OpenAlexW2151831055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.